MedTech Business - August 31, 2021
Photocure regains rights to Cysview in Canada
Photocure has reached agreement with BioSyent Pharma to reacquire the marketing and distribution rights to Cysview in Canada. The parties entered into a final agreement, stipulating that commercial rights will transfer to Photocure on January 1st, 2022. The reacquisition of marketing and distribution rights enables Photocure’s direct management of the Cysview brand in Canada and […]
Intellectual Property - February 18, 2020
Photocure announces new US patent for Hexvix
Photocure has announced that the United States Patent and Trademark Office (USPTO) has granted US Patent covering the use of Blue Light Cystoscopy (BLC) with Hexvix as neoadjuvant therapy in the treatment of bladder cancer in patients who are scheduled for a cystectomy. Early stage study results have shown an anti-tumor effect and induced systemic […]
Agreement - July 1, 2019
Photocure enters global licensing deal
The company has entered into a License Agreement providing Asieris Meditech with a world-wide license to develop and commercialize Cevira for the treatment of HPV induced cervical precancerous lesions. Asieris plans to launch a global clinical development program with an initial focus on the China market based on Photocure’s Phase 2b data and the Phase […]
Drug Development Pharma - September 7, 2017
Positive results from Photocure
Photocure reports that a prospective controlled study investigating the introduction of Blue Light Cystoscopy (BLC) with Hexvix at first presentation in patients with non-muscle invasive bladder cancer (NMIBC) in routine clinical practice has been published in the World Journal of Urology. The overall recurrence rates at 3 years were significantly less in patients who received […]
Clinical Trials Medtech - May 12, 2016
Photocure presents positive data
Norwegian Photocure has announced new data from a prospective multicenter ongoing registry study that shows Blue Light Cystoscopy (BLC) with Cysview increases detection rates of flat, more aggressive non-muscle invasive bladder cancer lesions (carcinoma in situ (CIS)) as well papillary lesions over white light cystoscopy (WLC) alone. The data from the prospective registry, real life, […]
Intellectual Property - March 16, 2016
Photocure announces grant of patents for CEVIRA
Oslo Cancer Cluster member Photocure announces that a new patent for Cevira has been granted in Europe. Cevira is one of Photocure’s promising pipeline products and is being developed as a new and innovative breakthrough for the treatment of precancerous lesions of the cervix. The newly granted patent protects the Cevira drug, its use and […]
